CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2b, Randomized, Multicenter, Double-blind, Parallel Group, Placebo Controlled, Dose Ranging Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05279417
Title field or adapter rule: {'original_value': 'Phase 2b, Randomized, Multicenter, Double-blind, Parallel Group, Placebo Controlled, Dose Ranging Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-30T23:06:05.454466+00:00
Published At: 2026-09-28T00:00:00+00:00
Record Updated At: 2026-09-28
Results Posted At: 2026-09-28
Source Retrieved At: 2026-10-30T22:08:09.759186+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Rheumatoid Arthritis"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-09-28", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT05279417"
protocolSection.identificationModule.officialTitle: "Phase 2b, Randomized, Multicenter, Double-blind, Parallel Group, Placebo Controlled, Dose Ranging Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: {"date": "2026-09-28", "type": "ACTUAL"}

{'armGroupLabels': ['ATI-450 50 mg BID plus Methotrexate'], 'description': 'Oral, small molecule MK2 inhibitor', 'name': 'ATI-450 50 mg oral tablet BID', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Placebo plus Methotrexate'], 'description': 'Placebo tablet manufactured to match ATI-450 in appearance', 'name': 'Placebo oral tablet', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['ATI-450 20 mg BID plus Methotrexate', 'ATI-450 50 mg BID plus Methotrexate', 'Placebo plus Methotrexate'], 'description': '15 mg to 25 mg weekly', 'name': 'Methotrexate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['ATI-450 20 mg BID plus Methotrexate'], 'description': 'Oral, small molecule MK2 inhibitor', 'name': 'ATI-450 20 mg oral tablet BID', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.